Aligos Therapeutics, Inc.(ALGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALGS Aligos Therapeutics, Inc.

Trading 07-17 12:48:00 EDT

5.79

+0.04

+0.70%

High5.84	Low5.60	Vol11.90K
Open5.70	D1 Closing5.75	Amplitude4.09%
Mkt Cap35.83M	Tradable Cap21.08M	Total Shares6.19M
T/O68.70K	T/O Rate0.33%	Tradable Shares3.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALGS","market":"US","secType":"STK","nameCN":"Aligos Therapeutics, Inc.","latestPrice":5.79,"timestamp":1784306869745,"preClose":5.75,"halted":0,"volume":11903,"delay":0,"changeRate":0.006956521739130441,"floatShares":3641200,"shares":6188200,"eps":-8.698447,"marketStatus":"Trading","change":0.04,"latestTime":"07-17 12:48:00 EDT","open":5.7,"high":5.835,"low":5.6,"amount":68698.426366,"amplitude":0.04087,"askPrice":5.83,"askSize":4,"bidPrice":5.78,"bidSize":183,"shortable":3,"etf":0,"ttmEps":-8.698447,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784318400000},"marketStatusCode":2,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":5.75,"preHourTrading":{"tag":"盘前","latestPrice":5.59,"preClose":5.75,"latestTime":"09:25 EDT","volume":322,"amount":1789.999932,"timestamp":1784294731880,"change":-0.16,"changeRate":-0.027826,"amplitude":0.013913},"postHourTrading":{"tag":"盘后","latestPrice":5.75,"preClose":5.75,"latestTime":"17:53 EDT","volume":146,"amount":840.85,"timestamp":1784238824050,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.223727,"impliedVol":0.1576,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ALGS","defaultTab":"news","newsList":[{"id":"2651217421","title":"Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2651217421","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651217421?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:15","pubTimestamp":1784024151,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright rei...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-aligos-therapeutics-maintains-50-price-target-amid-strengthened-hbv-trial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-aligos-therapeutics-maintains-50-price-target-amid-strengthened-hbv-trial-outlook-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651192331","title":"Aligos Completes Enrollment in Phase 2 B-supreme Trial for Chronic Hepatitis B Drug Pevifoscorvir Sodium","url":"https://stock-news.laohu8.com/highlight/detail?id=2651192331","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651192331?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:05","pubTimestamp":1783944349,"startTime":"0","endTime":"0","summary":"Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodiumAligos completed enrollment in its Phase 2 B-SUPREME trial of pevifoscorvir sodium for chronic h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL9PSzhn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2W23.USD","BK4588","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","BK4505","LU2210150020.SGD","LU2095319765.USD","ALGS","BK4139","IE00BN0W2V16.EUR","NDAQ","LU2210149790.SGD","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651511963","title":"Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-supreme Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic Hbv Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2651511963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651511963?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA89GGVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","ALGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196951","title":"Aligos Therapeutics - Topline Safety and Efficacy Data Expected in Late Q3 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651196951?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA89GGVZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651611110","title":"Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2651611110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651611110?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944000,"startTime":"0","endTime":"0","summary":"Topline data expected to be available late 3Q2027SOUTH SAN FRANCISCO, Calif., July  13, 2026  (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326139/0/en/Aligos-Therapeutics-Announces-the-Completion-of-Enrollment-in-the-Phase-2-B-SUPREME-Study-of-Pevifoscorvir-Sodium-Under-Development-for-the-Treatment-of-Chronic-HBV-Infection.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALGS","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649674118","title":"Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2649674118","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649674118?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:53","pubTimestamp":1783374780,"startTime":"0","endTime":"0","summary":"Shares of Aligos Therapeutics surged after the company received a $25 million upfront payment as part of a licensing deal with Xiamen Amoytop Biotech.The stock was up 20% to $7.02 in after-hours trading Monday. Shares closed the market session up 4.7% at $5.85, but are still down 37% this year.The pact between the two companies is for pevifoscorvir sodium, a hepatitis B treatment, in Greater China.Aligos said it was eligible to receive up to $420 million in payments based on clinical, regulatory and sales milestones. The clinical stage biopharmaceutical company also said it may receive tiered, high-single-digit royalties on net sales in Amoytop's licensed territories.Aligos retains all development and commercialization rights for pevifoscorvir sodium in all other markets, including the U.S., Europe and South Korea.Chief Executive Lawrence Blatt said Amoytop would introduce Aligos' antisense oligonucleotide into the clinic in China in the third quarter.Write to Grace Yoon at grace.yoon@","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ALGS","688278","BK4588","BK4585","BK0239","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679715","title":"Aligos Rises on Receiving Upfront Payment from Hepatitis B Drug License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679715","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679715?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:19","pubTimestamp":1783369179,"startTime":"0","endTime":"0","summary":"BUZZ-Aligos rises on receiving upfront payment from hepatitis B drug license deal** Shares of biotech firm Aligos TherapeuticsALGS.Ojump 23.1% to $7.2O after the bell** ALGS says has received upfront ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nL4N4381CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","688278","ALGS","BK4139","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649790656","title":"Aligos Therapeutics receives $25M upfront for pevifoscorvir sodium license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2649790656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649790656?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:10","pubTimestamp":1783368608,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) announced that it has received the upfront payment of $25M from the exclusive license deal of pevifoscorvir sodium in Gr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-receives-25m-upfront-for-pevifoscorvir-sodium-license-deal-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-receives-25m-upfront-for-pevifoscorvir-sodium-license-deal-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","ALGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867992","title":"Aligos Therapeutics Receives USD 25 Million Upfront in Greater China Pevifoscorvir License Deal with Amoytop","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867992","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649867992?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368350,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with AmoytopAligos received an upfront payment of USD 25 million from an exclusive Greater China license","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL6G1l1M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BCDF","IE00BGHQF748.EUR","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4139","SG9999014013.SGD","BK4585","SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4505","NDAQ","IE00BKPKM429.USD","BK4588","ALGS","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679947","title":"Aligos Therapeutics - Eligible for up to $420 Mln in Milestones and Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679947?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368314,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380IM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679946","title":"Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679946?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368314,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","ALGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646600713","title":"Aligos Therapeutics Shareholders Approve Directors and Governance Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646600713","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646600713?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:37","pubTimestamp":1782506269,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics ( ($ALGS) ) has provided an announcement. On June 25, 2026, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aligos-therapeutics-shareholders-approve-directors-and-governance-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aligos-therapeutics-shareholders-approve-directors-and-governance-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","ALGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646367024","title":"Aligos Therapeutics Shareholders Approve ESPP Share Reserve Increase, Remove Evergreen Provision","url":"https://stock-news.laohu8.com/highlight/detail?id=2646367024","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646367024?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:03","pubTimestamp":1782504187,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics shareholders approve ESPP share reserve increase, remove evergreen provisionAligos Therapeutics held its annual shareholder meeting on June 25, 2026.Shareholders adopted an amendme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL50sjCm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALGS","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641124933","title":"Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641124933","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641124933?lang=en_us&edition=fundamental","pubTime":"2026-06-06 21:06","pubTimestamp":1780751214,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-algs/aligos-therapeutics/news/heres-why-were-a-bit-worried-about-aligos-therapeutics-nasda-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-algs/aligos-therapeutics/news/heres-why-were-a-bit-worried-about-aligos-therapeutics-nasda-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","QDTE","TQQY","QQQM","NVIW.SI","ONEQ","TQQQ","NDX","QYLG","QLD","PSQ","TECS","BK4139","JEPQ","QID","FTEC","GPIQ","QQQ","IYW","QQQA","QQQY","QQQE","NQmain","SQQQ","QQQJ","MNQmain",".IXIC","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640761950","title":"Analysts Are Bullish on Top Healthcare Stocks: Aligos Therapeutics (ALGS), Jade Biosciences (JBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640761950","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640761950?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:30","pubTimestamp":1780324206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS) and Jade Biosciences (JBI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aligos-therapeutics-algs-jade-biosciences-jbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aligos-therapeutics-algs-jade-biosciences-jbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","JBIO","BK4139","ALGS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639690179","title":"Aligos Therapeutics Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639690179?lang=en_us&edition=fundamental","pubTime":"2026-05-29 01:28","pubTimestamp":1779989280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALGS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 13:28 ET (17:28 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","ALGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638694868","title":"Analysts’ Top Healthcare Picks: Aligos Therapeutics (ALGS), Equillium (EQ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638694868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638694868?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:40","pubTimestamp":1779979208,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS) and Equillium (EQ) with b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-aligos-therapeutics-algs-equillium-eq-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-aligos-therapeutics-algs-equillium-eq-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0128526141.USD","BK4568","BK4581","BK4137","BK4139","ALGS","BK4588","LABU","HCSG","XBI","LU0029874061.USD","XLV","EQ","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638681699","title":"Aligos Therapeutics initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2638681699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638681699?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:28","pubTimestamp":1779974896,"startTime":"0","endTime":"0","summary":"Lake Street analyst Daniel Brims initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $45 price target based on the market opport...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-initiated-with-a-buy-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-initiated-with-a-buy-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698441","title":"Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698441","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698441?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:04","pubTimestamp":1779969888,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) has an average rating of Buy and mean price target of $56.29, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638505872","title":"Aligos Therapeutics presents data at EASL congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2638505872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638505872?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:15","pubTimestamp":1779873309,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) announced data from ten presentations at the European Association for the Study of the Liver, or EASL, Congress 2026, be...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-presents-data-at-easl-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-presents-data-at-easl-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","ALGS","EPV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aligos.com","stockEarnings":[{"period":"1week","weight":-0.1507},{"period":"1month","weight":0.1523},{"period":"3month","weight":-0.1392},{"period":"6month","weight":-0.2758},{"period":"1year","weight":-0.3376},{"period":"ytd","weight":-0.383}],"compareEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.0854},{"period":"1year","weight":0.2027},{"period":"ytd","weight":0.1009}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.020655},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.084797},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.197646},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.12162},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.029634},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.083851},{"month":7,"riseRate":0.5,"avgChangeRate":0.024679},{"month":8,"riseRate":0.6,"avgChangeRate":0.114051},{"month":9,"riseRate":0,"avgChangeRate":-0.14617},{"month":10,"riseRate":0.4,"avgChangeRate":-0.048799},{"month":11,"riseRate":0.666667,"avgChangeRate":0.350449},{"month":12,"riseRate":0.333333,"avgChangeRate":0.114782}],"exchange":"NASDAQ","name":"Aligos Therapeutics, Inc.","nameEN":"Aligos Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aligos Therapeutics, Inc.(ALGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aligos Therapeutics, Inc.(ALGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aligos Therapeutics, Inc.,ALGS,Aligos Therapeutics, Inc.股票,Aligos Therapeutics, Inc.股票老虎,Aligos Therapeutics, Inc.股票老虎国际,Aligos Therapeutics, Inc.行情,Aligos Therapeutics, Inc.股票行情,Aligos Therapeutics, Inc.股价,Aligos Therapeutics, Inc.股市,Aligos Therapeutics, Inc.股票价格,Aligos Therapeutics, Inc.股票交易,Aligos Therapeutics, Inc.股票购买,Aligos Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aligos Therapeutics, Inc.(ALGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aligos Therapeutics, Inc.(ALGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction